UNSPSC 51282303: Dirithromycin

This classification denotes a macrolide antibiotic with the molecular formula C42H78N2O14, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1801D76STL, chemically known as erythromycin, 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethylidene)oxy)-, (9s(r))- but generally known as dirithromycin, which bears US NIH Compound Identifier 5464388. European Medicines Agency schedules Dirithromycin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07232MIG.

UNSPSC 51282303 Dirithromycin, a Commodity code, nominally covers a specific macrolide antibiotic, but recent state and local procurement activity under this code actually encompasses a broader range of pharmaceutical products and medical supplies—naloxone, over-the-counter medications, generic multi-source pharmaceuticals, and emergency medical consumables. State and local agencies are sourcing these items through competitive bidding (IFB), requests for proposal (RFP), and requests for information (RFI) to support public health, emergency response, and state employee benefit programs. Issuing bodies include county health departments, city fire rescue divisions, state pharmacy benefit programs, and state procurement offices managing cooperative purchasing agreements on behalf of multiple jurisdictions.

Recent opportunities span Florida, Texas, Minnesota, and Oregon through cooperative purchasing vehicles. The Seminole County, Florida IFB (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually for community health initiatives. The City of Tampa issued an IFB (26P00145, due March 13, 2026) for 169 line items of medical and first aid supplies including respiratory equipment, cardiac monitoring electrodes, and medical consumables for the Tampa Fire Department Rescue Division, with an estimated contract value of $700,000 and a 5 percent bid discount reserved for certified Small Local Business Enterprises. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802, due March 26, 2026) to establish contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, requiring vendors to supply through three authorized wholesalers and certifying compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission posted an RFI (HHS0017013, posted April 3, 2026) to gather market intelligence on direct-to-manufacturer prescription programs outside of existing pharmacy benefit manager arrangements.